Cantor Fitzgerald Estimates EYPT FY2026 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings per share of ($2.35) for the year. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

A number of other research firms have also issued reports on EYPT. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, May 29th. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Mizuho cut their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Finally, Chardan Capital decreased their target price on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, EyePoint Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.38.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded up $0.17 during trading on Tuesday, hitting $9.03. 822,461 shares of the company were exchanged, compared to its average volume of 818,145. EyePoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $13.99. The stock has a 50 day moving average of $6.54 and a 200 day moving average of $6.93. The company has a market cap of $621.36 million, a PE ratio of -4.52 and a beta of 1.61.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, hitting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. grew its stake in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after buying an additional 1,940 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 3,174.4% during the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock worth $56,000 after acquiring an additional 9,936 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth $59,000. Virtus ETF Advisers LLC purchased a new position in EyePoint Pharmaceuticals in the fourth quarter worth $67,000. Finally, AlphaQuest LLC increased its stake in EyePoint Pharmaceuticals by 13,246.6% in the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock valued at $73,000 after acquiring an additional 9,670 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.